End-stage renal disease in Canada: Prevalence projections to 2005

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 11, 1999, Pages 1557-1563

  Schaubel, Douglas E ^a,b   Morrison, Howard I ^a   Desmeules, Marie ^a   Parsons, Daria A ^c   Fenton, Stanley S A ^d,e  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

^b IL   (United States)

^c CANADIAN INSTITUTE FOR HEALTH INFORMATION   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; COST OF ILLNESS; DIABETES MELLITUS; DIALYSIS; HEALTH CARE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROLOGY; PREVALENCE; REGISTER;

EID: 0033151923     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. 1. Canadian Organ Replacement Register, Canadian Institute for Health Information. Annual report 1998, volume 1: dialysis and renal transplantation. Information. Ottawa: The Register; 1998.
2. 2. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease. Clin Invest Med 1996;18:455-64.
3. 3. Desmeules M, Schaubel D, Fenton SSA, Mao Y. New and prevalent patients with end-stage renal disease in Canada: a portrait of the year 2000. ASAIO J 1995;41:230-3.
4. 4. Schaubel D, Morrison HI, Desmeules M, Parsons D, Fenton SSA. End-stage renal disease prevalence projections using Poisson and Markov models. Int J Epidemiol 1998;27:274-81.
5. 5. Frome EL. The analysis of rates using Poisson regression models. Biometrics 1983;39:665-74.
6. 6. Dobson AJ. An introduction to generalized linear models. New York: Chapman and Hall; 1990.
7. 7. Breslow NE. Extra-Poisson variation in log-linear models. Appl Stat 1984;33:38-44.
8. 8. Ross SM. Introduction to probability models. London (UK): Academic Press; 1989.
9. 9. Kjellstrand CM, Moody H. Hemodialysis in Canada: a first-class medical crisis. CMAJ 1994;150(7):1067-71.
10. 10. Mendelssohn DC, Chery A. Dialysis utilization in the Toronto region from 1981 to 1992. CMAJ 1994;150(7):1099-105.
11. 11. Martin M. As the number of patients grows, so do the critical problems facing MDs who provide dialysis. CMAJ 1996;154(6):931-3.
12. 12. Davies R, Johnson D, Farrow S. Planning patient care with a Markov model. Opl Res Q 1975;26:599-607.
13. 13. Farrow SC, Fisher DJH, Johnson DB. Statistical approach to planning an integrated haemodialysis/transplantation programme. BMJ 1971;2:671-6.
14. 14. Farrow SC, Fisher DJH, Johnson DB. Dialysis and transplantation: the national picture over the next five years. BMJ 1972;3:686-90.
15. 15. US Renal Data System 1995 annual report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
16. 16. Disney APS, editor: ANZDATA Report 1992. Adelaide (AS): Australia and New Zealand Dialysis and Transplant Registry; 1992.
17. 17. Raine AEG, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, et al. Report on management of renal failure in Europe, XXII, 1991. Nepbrol Dial Transplant 1992;71(Suppl 2):7-35.
18. 18. Port FK. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int 1995;48(Suppl 50):S3-6.
19. 19. Port FK. Worldwide demographics and future trends in end-stage renal disease. Kidney Int 1993;43(Suppl 41):S4-7.
20. 20. Hakulinen T, Teppo L. Do the predictions for cancer incidence come true? Experience from Finland. Cancer 1986;57:2454-8.
21. 21. Young EW, Mauger EA, Jiang KH, Port FK, Wolfe RA. Socioeconomic status and end-stage renal disease in the United States. Kidney Int 1994;45:907-11.
22. 22. Prevalence and incidence of diabetes mellitus - United States, 1980-1987. MMWR 1990;39:809-12.
23. 23. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642-52.
24. 24. Kinch N. Dialysis cost analysis. Mississauga (ON): Baxter Healthcare Corporation; 1992.